| Date |
Event |
Presentation |
Speakers |
|
February 20, 2012
|
Advances and Progress in Drug Design
|
Molecular obesity, potency and other addictions in medicinal chemistry
|
Mike Hann,
|
|
November 3, 2010
|
DIA’s 8th Annual Canadian Meeting: “Keeping Canada on the Map: Fostering Innovation and Access to Drugs in Canada�
|
International Collaboration: An Industry Perspective
|
Neerja Goyal
|
|
April 28, 2010
|
HCV Drug Discovery
|
Boron and Non-Boron-Based HCV NS3/4 Protease InIhibitors: Discovery of a Novel Motif Possessing High Potency against PI-Resistant Mutants
|
Wieslaw Kazmierski
|
|
November 13, 2009
|
Globalization and standardization: Agreements-Budget-Regulation-Operations.
|
New Presentation
|
Dora MATHIASZ
|
|
November 3, 2009
|
ASAP-CHI Bio-Pharma Alliance Summit, Driving success with Effect ive Biotech/ Pharma Alliances
|
Launching the Alliance: What Big Pharma and Biotech Companies Need to Know
|
Bill Wilkison
|
|
November 2, 2009
|
Track 3: Fourth Annual Ion Channels as Therapeutic Targets
|
Title to be Announced
|
Derek J. Trezise
|
|
July 28, 2009
|
European Regulatory Affairs Summer School
|
Introduction to the eCTD and basic principles
|
Lillian Reilly
|
|
June 9, 2009
|
Cell and Tissue-Based Assays for HTS
|
Novel Assays and New Technologies
|
Kalpana Patel
|
|
|
|
Table Six: Novel Assays, New Technologies and their Applications
|
Kalpana Patel
|
|
June 9, 2009
|
Third Annual Cardiotoxicity and Drug Safety
|
Use of Cardiac Troponin Measurements in Drug Development For the Detection of Cardiotoxicity
|
John K. Finkle
|
|
June 9, 2009
|
Translating Genomic Knowledge
|
Chairperson’s Remarks
|
Eric C Lai
|
|
|
|
Panel Discussion – Successful Data Flow in Translation Discovery Research
|
Eric C Lai
|
|
|
|
Integrating Pharmacogenetics Throughout the Pharma Value Chain
|
Daniel K. Burns
|
|
April 22, 2009
|
PI 3-Kinase Signaling in Disease (Z3)
|
PI 3-Kinase Pathway Modulation: Transition to the Clinic I
|
Richard F Wooster
|
|
April 21, 2009
|
3rd Annual Clinical Trials in Emerging Economies
|
Opening remarks from the chairperson
|
Allan Pamba
|
|
|
|
Closing remarks from the chairperson
|
Allan Pamba
|
|
|
|
Opening remarks from the chairperson
|
Allan Pamba
|
|
|
|
Challenges and Lessons from a large Phase III clinical trial in Sub Saharan Africa
|
Allan Pamba
|
|
|
|
Closing remarks from the chairperson
|
Allan Pamba
|
|
February 24, 2009
|
11th National Conference on Managing Legal Risks in Structuring & Conducting Clinical Trials
|
Workshop B: International Clinical Trials Boot Camp: The A to Z guide of essentials you need to know before going overseas
|
Elizabeth M Zechenter
|
|
February 23, 2009
|
Advances and Progress in Drug Design VIII
|
STRUCTURE BASED DRUG DESIGN WITH EMPHASIS ON GPCR MODELLING
|
Frank Blaney
|
|
February 8, 2009
|
CHEMISTRY IN CANCER RESEARCH: A Vital Partnership in Cancer Drug Discovery and Development
|
Session 5: Chemistry in Support of Lead Optimization/Case Histories I
|
Juan I Luengo
|
|
February 4, 2009
|
Adaptive Designs in Clinical Drug Development
|
Chairman's Opening Remarks
|
Alun Bedding
|
|
|
|
SIMULATION IN ADAPTIVE TRIALS : Statistical modelling and its application to adaptive trials
|
Alun Bedding
|
|
February 3, 2009
|
Ramanbhai Foundation 4th International Symposium ---Ramanbhai Foundation 4th International Symposium--- “Advances in Cardiometabolic Research - Basic Science and Clinical Aspects”
|
“Application of large-scale genetics to support drug discovery and development in the cardio-metabolic area”
|
Vincent Mooser
|
|
January 26, 2009
|
Biomarker Assay Development
|
Development and Integration of Biomarkers into Clinically Useful Diagnostics
|
Anne Marie Martin
|
|
January 26, 2009
|
Translational Cancer Medicine
|
Development and Integration of Biomarkers into Clinically Useful Diagnostics
|
Anne Marie Martin
|
|
January 26, 2009
|
7th Annual Partnering with Central Labs
|
B1 : How to Reduce the Burden on Smaller Sponsor Clinical Team-The Cross Functional Approach
|
Karen Turner
|
|
January 5, 2009
|
High Content Analysis
|
Primary HCS for Immunomodulation
|
Carmel B Nanthakumar
|
|
December 2, 2008
|
4th Annual Global Imaging Summit -The Application of Molecular and Cellular Imaging in Drug Discovery & Optimising Imaging Techniques in Preclinical and Clinical Drug Development
|
1: The synthesis and design of PET radiotracers
|
Anthony Gee,
|
|
|
|
2 : Opening remarks from the Chairperson
|
Phil Murphy,
|
|
|
|
2 : PET for managing the gap between laboratory and man - A Drug Company Perspective
|
Anthony Gee,
|
|
|
|
2 : Panel Debate: How translatable is preclinical and clinical imaging?
|
Phil Murphy,
|
|
|
|
2 : Closing remarks from the chairperson and end of conference day one
|
Phil Murphy,
|
|
|
|
2 : Opening remarks from the Chairperson
|
Phil Murphy,
|
|
|
|
2 : Exploiting the benefits of DCE MRI (Dynamic Contrast Enhanced-MRI) in the assessment of antiangiogenic agents
|
Phil Murphy,
|
|
|
|
2 : Closing remarks from the chairperson and end of conference
|
Phil Murphy,
|
|
December 2, 2008
|
2nd Annual Lead Discovery Summit 2008:-Compound Library Design, Synthesis & Acquisition
|
Ion channel modulators: a knowledge driven approach
|
Véronique Birault,
|
|
|
|
Fragment based design and ligand efficiency – concepts and practice
|
Mike Hann,
|
|
|
|
Experience of outsourcing to India and China
|
Duncan Judd,
|
|
|
|
Biological fingerprints: Acceleration of hit identification and decision making in drug discovery
|
Wolfgang Jarolimek,
|
|
December 2, 2008
|
The 8th World Drug Discovery & Development Summit 2008
|
THE INDUSTRIALISATION OF CELLULAR SCREENING
|
Alan Wise
|
|
November 12, 2008
|
Third Annual Post-Approval Drug Safety Strategies: Best Practices to Mitigate Risks throughout the Product's Life Cycle
|
Genomics Role in Safety: Moving from Observation to Prediction & Leveraging New Tools and Thinking
|
Dan Burns
|
|
November 5, 2008
|
DIA's 6th Canadian Annual Meeting: Benefit and Risk Management: An Evolution in Progress
|
CANADIAN STEERING COMMITTEE
|
RAV KUMAR
|
|
|
|
COMMUNICATION OF BENEFIT/RISK (SAFETY ISSUES)
|
DAVID , KRAKOVSKY
|
|
October 12, 2008
|
15th North American Regional Meeting - International Society for the Study of Xenobiotics
|
Drug Induced Vascular Injury
|
Brian R. Berridge
|
|
|
|
Can Plasma Protein Binding Represent a Safety Issue for Drug Development? The Radafaxine Case
|
Paolo Rossato
|
|
October 8, 2008
|
Accelerating Proof Of Concept
|
Implementing New Approaches for Increasing Productivity of Drug Development
|
Dongzhou J. Liu
|
|
September 17, 2008
|
BACULOVIRUS TECHNOLOGY
|
Engineering A Better CHO Cell Host for Baculovirus Transduction
|
Patrick Condreay
|
|
March 30, 2008
|
Nuclear Receptors: Steroid Sisters
|
Drug Development
|
Dennis Sprecher
|
|
March 30, 2008
|
Nuclear Receptors: Orphan Brothers
|
Drug Development
|
Dennis Sprecher
|
|
March 25, 2008
|
Preclinical Development
|
Advances in Liver Toxicity Testing: What’s on the Horizon?
|
Holly L Jordan
|
|
March 25, 2008
|
TRENDS IN DRUG SAFETY
|
Advances in Liver Toxicity Testing: What’s on the Horizon?
|
Holly L Jordan
|
|
February 19, 2008
|
Screening Europe
|
Track B The Industrialisation of 1536 Well Format High Throughput Screening for Modulators of G Protein-Coupled Receptors
|
Stuart Baddeley
|
|
November 26, 2007
|
Obesity Drug Development World 2007
|
Targeting the Sodium Glucose Transporter II and developing selective inhibitors
|
Chari Smith
|
|
|
|
Panel session: additional Q&A on SGLT2, GKA and GLP-1
|
Chari Smith
|
|
November 7, 2007
|
Bridging the Business Development/Alliance Management Interface Nov(7-8)
|
Leveraging the Power of a Strong Alliance - GlaxoSmithKline’s Center of Excellence for Drug Discovery (08:45-09:30)
|
Mark Strobeck
|
|
November 7, 2007
|
Stem Cells and Primary Cells in Drug Discovery
|
Welcome Remarks
|
Robert Ames
|
|
November 4, 2007
|
AACR Centennial Conference: Translational Cancer Medicine
|
Concurrent Session 1: Clinical Pharmacogenetics: Assessing Global Diversity
|
Eric C Lai
|
|
|
|
Concurrent Session 3: Hereditary Cancers
|
Richard WOOSTER
|
|
October 17, 2007
|
Second Annual Ion Channels: An Emerging Target for Therapeutic Development Oct (17-18)
|
TECHNOLOGIES FOR ION CHANNEL DRUG DISCOVERY (09:40-12:25)
|
Derek J. Trezise
|
|
|
|
TECHNOLOGIES FOR ION CHANNEL DRUG DISCOVERY: Novel Applications of Planar Array Electrophysiology in Ion Channel Drug Discovery (10:55-11:25)
|
Derek J. Trezise
|
|
|
|
TARGETING PAIN MANAGEMENT: Chairperson’s Remarks (13:55-14:00)
|
Iain Chessell
|
|
|
|
TARGETING PAIN MANAGEMENT (13:55-17:10)
|
Iain Chessell
|
|
|
|
TARGETING PAIN MANAGEMENT: Novel and Translatable Mechanisms for Pain Treatment - Lessons From the P2X Receptor Family (14:00-14:30)
|
Iain Chessell
|
|
October 16, 2007
|
Second Annual Putting Theory into Practice: Adaptive Clinical Trial Designs (Oct 16-17
|
SESSION I: Setting the Stage for Adaptive Design Trials (14:00 - 14:30)
|
Judith A. Quinlan
|
|
|
|
SESSION I: LAYING THE GROUND WORK FOR EARLY DECISION MAKING (13:45 - 19:00)
|
Judith A. Quinlan, Graeme E. Archer
|
|
|
|
SESSION I: The Use of Bayesian Methods in Go/No-Go Decision Making (15:00 - 15:30)
|
Graeme E. Archer
|
|
|
|
SESSION II: REGULATORY PERSPECTIVES AND LESSONS LEARNED FROM CONDUCTING STUDIES WITH ADAPTIVE TRIAL DESIGNS (08:30-11:15)
|
Judith A. Quinlan
|
|
|
|
SESSION II: Co-Chairperson’s Opening Remarks (08:30-08:45)
|
Judith A. Quinlan
|
|
|
|
CASE STUDIES (11:15-14:45)
|
Judith A. Quinlan
|
|
|
|
CASE STUDY: Acute Migraine POC Using CRM - The Power of Team Work and a Can Do Attitude... Overcoming Logistical and Operational Hurdles (13:45-14:15)
|
Judith A. Quinlan
|
|
October 15, 2007
|
2nd Annual Innovations in Clinical Trials: Implementations of Biomarkers (Oct15-16)
|
BIOIMAGING FOR MONITORING RESPONSE TO THERAPY, DOSE SELECTION, ASSESSING MOLECULAR ACTIVITY AND RECEPTOR OCCUPANCY (08:00-13:30)
|
Robert A. Comley
|
|
|
|
PET Receptor Occupancy - Accelerating Drug Development by Non-Invasive Measurement of Drug Action Early in the Development Pipeline (09:05-09:35)
|
Robert A. Comley
|
|
October 11, 2007
|
Compound Profiling & Chemogenomic Approaches to Drive Decision Making and Predict Clinical Adverse Effects (Oct 11-12)
|
SELECTING LEADS AND DETECTING ADVERSE ACTIVITY (14:00-17:30)
|
Dana E. Vanderwall
|
|
|
|
SELECTING LEADS AND DETECTING ADVERSE ACTIVITY: Analysis of Biological Mechanism of Action, and Characterization of Profiles across the Progression Path (14:05-14:35)
|
Dana E. Vanderwall
|
|
October 2, 2007
|
IVT 's Lab Week
|
Stability Programs Regulatory Requirements | Track B Building a Compliant Laboratory
|
Yin Jiang
|
|
|
|
Type of Stability Studies | Track B Building a Compliant Laboratory
|
Yin Jiang
|
|
|
|
Batch Selection, Interval, and Storage Condition | Track B Building a Compliant Laboratory
|
Yin Jiang
|
|
|
|
Interactive Exercise | Track B Building a Compliant Laboratory
|
Yin Jiang
|
|
|
|
cGMP Regulations | Track B Building a Compliant Laboratory
|
Yin Jiang
|
|
|
|
State of Control | Track B Building a Compliant Laboratory
|
Yin Jiang
|
|
|
|
Lean Lab | Track B Building a Compliant Laboratory
|
Yin Jiang
|
|
|
|
Lab Operational Excellence | Track B Building a Compliant Laboratory
|
Yin Jiang
|
|
|
|
Interactive Exercise | Track B Building a Compliant Laboratory
|
Yin Jiang
|
|
September 24, 2007
|
High-Content Analysis Europe: High content Cellular Assays for compound screening and Pahtway Analysis (Sep 24-26)
|
HCA for Mechanism-of-Action Studies: Use of the BD Pathway in CNS Drug Discovery to Determine Mechanisms of Compound Action in Primary Neuronal Cultures (16:00-16:30)
|
Claire Scott
|
|
|
|
HCA for Mechanism-of-Action Studies (16:00-18:00)
|
Claire Scott
|
|
September 19, 2007
|
Baculovirus Technology (Sep 19-20)
|
Baculovirus: The Big Picture (08:30-10:35)
|
Michel Deschuyteneer
|
|
|
|
Baculovirus - The Big Picture: FEATURED SPEAKER - Quality Assessment of GSK’s Cervical Cancer Candidate Vaccine Manufactured with the Baculovirus Expression Vector System (BEVS) (09:20-10:00)
|
Michel Deschuyteneer
|
How We Rank